

August 9, 2023 11:01 PM GMT

Solutions by STC | Europe

Time for a valuation pause

STOCK RATING INDUSTRY VIEW PRICE TARGET Equal-weight No Rating SAR 303.00

Despite the recent stock pull-back, after strong YTD share price performance we see the current valuation as sufficiently capturing the investment opportunity. We increase our FY24/25 adj. EPS forecasts by 3/4% post 2Q earnings.

| WILLATIO | OLIANIOED |
|----------|-----------|
| WHAI 5 | CHANGED |

| Solutions by STC (7202.SE) | From | То |
|----------------------------|------------|------------|
| Price Target | SAR 295.00 | SAR 303.00 |

Organic growth slowdown is an investor focus in 2Q reporting: Despite Solutions delivering another profit beat at 2Q, the stock has underperformed since the details were released, trading down to SAR 321, compared to its recent SAR 360-380 trading range. We think there are two factors for this: 1) Solutions is a growth story, and 2Q represented a significant consensus profit beat, but missed revenue expectations by c. 3%, and 2) Solutions' rate of organic growth was disclosed at only c. 5% for 1H23. We think this second point is most important. With recent acquisitions of Giza Systems and Contact Center Company (CCC), disclosure around precise organic growth rates was not clear, until 2Q, and the newly disclosed level of c. 5% is lower than the high-single-digit % we were modelling for 1H23. It also puts into context the growth moderation that Solutions has seen, from (we estimate) c. 30%/31%/13%/13% in FY19/20/21/22.

Where does organic growth inflect next? Firstly, we note that the organic growth disclosure by Solutions (i.e. 5% y/y growth in 1H23) may be slightly too punitive a calculation. The company flagged on the 2Q conference call that - since acquisition some revenues are now channelled through Giza (and i.e. out of core Solutions). Stepping back, we do not have significant structural concerns around Solutions' market opportunity. The market backdrop remains supportive, with fiscal spend around Vision 2030, and digitalisation of the economy; IDC calculate that the IT Services market will grow at a c. 9% CAGR 2022-27. Where there is volatility in Solutions' numbers is around the Core ICT Services business, which is a mix of lower market growth Communications & Internet services, and higher growth, but more lumpy System Integration (SI) revenues. SI revenues are project-based (often 12-18 month contracts), and so are lumpier in nature; therefore visibility is lower. We suspect growth in Core ICT Services in 1H has been the lowest amongst the three group divisions, partly against a tough prior-year base comp. All things considered, we expect Solutions to continue to grow revenues broadly in-line with market growth, on an organic basis (MSe c. 8-9% p.a. through to FY26). Our base assumption is that Solutions' scope to take meaningful further market share from here organically is relatively limited given its c. 20% market share position in 2022 (towards the higher end of what we observe in developed European markets).

MORGAN STANLEY & CO. INTERNATIONAL PLC+

George W Webb

Equity Analyst

George.Webb@morganstanley.com +44 20 7425-2686

Henrik Herbst

Equity Analyst

Henrik.Herbst@morganstanley.com +44 20 7677-1309

Mark Hyatt

Equity Analyst

Mark.Hyatt@morganstanley.com +44 20 7677-3663

Adam Wood

Fauity Analyst

Adam.Wood@morganstanley.com +44 20 7425-4450



Solutions by STC (7202.SE, SOLUTION AB)

EEMEA - Technology | Saudi Arabia

| Stock Rating | Equal-weight |
|--------------------------------|--------------------|
| Industry View | No Rating |
| Price target | SAR 303.00 |
| Shr price, close (Aug 9, 2023) | SAR 320.80 |
| 52-Week Range | SAR 385.00- 216.80 |
| Mkt cap, curr (mn) | SAR 38,496 |
| Net debt (12/23e) (mn)* | SAR (2,735) |
| EV. curr (mn)* | SAR 35.977 |

* = GAAP or approximated based on GAAP

| Fiscal Year Ending | 12/22 | 12/23e | 12/24e | 12/25e |
|-------------------------------|---------|---------|---------|---------|
| Sales / Revenue (SAR mn)** | 8,805 | 11,051 | 12,279 | 13,363 |
| EBITDA (SAR mn)** | 1,389 | 1,839 | 1,901 | 2,069 |
| EBIT (SAR mn)** | 1,162 | 1,589 | 1,615 | 1,761 |
| EPS (SAR)** | 8.97 | 11.89 | 12.13 | 13.30 |
| ModelWare EPS (SAR) | 8.97 | 11.89 | 12.13 | 13.30 |
| Prior EPS (SAR)** | 8.97 | 10.87 | 11.76 | 12.74 |
| EPS (SAR)§ | 8.85 | 10.55 | 12.30 | 13.27 |
| P/E** | 27.1 | 27.0 | 26.5 | 24.1 |
| EV/revenue* | 3.0 | 3.3 | 2.9 | 2.9 |
| EV/EBITDA** | 19.2 | 19.7 | 18.7 | 18.7 |
| EV/EBIT** | 22.9 | 22.8 | 22.1 | 21.9 |
| DPS (SAR) | 5.00 | 5.50 | 5.85 | 6.15 |
| Div yld (%) | 2.1 | 1.7 | 1.8 | 1.9 |
| FCF yld ratio (%)** | 6.8 | 3.1 | 3.5 | 4.1 |
| Net debt (SAR mn)* | (2,548) | (2,735) | (3,411) | (4,280) |
| Net debt/EBITDA** | NM | NM | NM | NM |

Unless otherwise noted, all metrics are based on Morgan Stanley ModelWare framework

- ** = Based on consensus methodology
- § = Consensus data is provided by Refinitiv Estimates

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

+= Analysts employed by non-U.S. affiliates are not registered with FINRA, may not be associated persons of the member and may not be subject to FINRA restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Valuation looks up with events: At SAR 321, Solutions trades on c. 26.5x FY24 adj. P/E on our updated forecasts, or a c. 3.4% FCF yield. The stock has been strongly supported since IPO by material revenue growth outperformance, with 2Q marking a departure from that trend. Growth remains strong at the group level, but now much more backed by inorganic growth. Solutions continues to have clear firepower to conduct M&A (c. SAR 1.9bn of net cash at 1H23 end), though Solutions does not yet (in our view) have an M&A track record, given the recent nature of the Giza and CCC deals. Our DCF-derived price target implies modest downside, and a c. 25x FY24 adj. P/E multiple, reflecting Solutions' medium-term runway for solid growth. In Exhibit 1, we map FY24 adj. P/E vs. FY25 adj. EPS growth across our broader European IT Services coverage, select US large-cap peers, Indian heritage vendors, and KSA-peer, Elm Company.


How might generative Al impact the IT services markets? In June, in combination with our global colleagues, we published a report looking at the impact of AI on IT services vendors: Global IT Services: AI - At your service. While we have not heard this as a widespread discussion topic within the KSA community with respect to Solutions by STC, it has become an important discussion point around the European and US IT services spaces. In short, we see IT services vendors overall as near-term Al beneficiaries. With most companies in the early innings of their digital transformations, on a 1-3 year view we see a demand tailwind as companies look to IT Services vendors to help them understand their data landscape and ways to leverage AI. In addition, vendors who internally adopt AI tools early could benefit from productivity and margin benefits. However, we expect these benefits to be small and limited to early adopters as: (1) productivity savings are likely shared with customers, and (2) IT Services vendors strategically invest to build AI capability. However, the longer-term market impact is less clear, and could in our view swing net positively or net negatively for the IT services industry. We outline bull and bear scenarios in our Executive Summary within the linked note.

Forecasts increased post 2Q earnings as gross margin leverage shows through, remaining above (upgraded) guidance, price target raised to SAR 303: Despite a more muted top-line performance versus consensus expectations in 2Q, Solutions comfortably beat on gross profit performance, fuelling a bottom-line beat. Looking past movements in impairments/provisions, we calculate a c. 17.9% adj. EBIT margin for 2Q, significantly above 14.7% in 1Q and 13.2% for FY22. Given this is driven by gross margins - which can be volatile - we do not assume this persists through H2. For context, in FY22, the 1H/2H adj. EBIT margin split was 14.7%/11.7%. In our updated forecasts, our top-line expectations are raised 1%, reflecting revised M&A contribution estimates, and slightly lowered pro-forma organic growth within the mix (down to 8.7% for the year). However, partly reflecting overall gross margin performance and cost structure growth, we raise our adj. EBIT margin forecasts, driving a c. 6/7% uplift to FY24/25 adj. EBIT. With slightly higher Zakat rates assumed, our adj. diluted EPS forecasts are raised 9/3/4% for FY23/24/25 (see Exhibit 4). Our FY23 % change is higher than FY24/25, reflecting our assumption that gross margins normalise back into the 22-23% from FY24. We remain above the newly upgraded revenue growth guidance of 19-22% (MS 26%) and re-iterated EBITDA margin guidance of 13-15% (MS 15.5%). Our DCF-derived price target tracks higher, to SAR 303 (up from SAR 295).

- * = GAAP or approximated based on GAAP
- e = Morgan Stanley Research estimates

Supporting exhibits

Exhibit 1: CY24 adj. P/E vs. CY25 adj. EPS growth: Solutions valuation vs. European IT Services vs. US large-caps vs. Indian heritage vendors vs. ELM




Source: Morgan Stanley Research estimates (for covered companies). Refinitiv consensus, ex-outliers, CY24 adj. EPS growth used where CY25 not available, *stated EPS

Exhibit 2: Revenue growth vs. organic growth over time



Source: Company data, Morgan Stanley Research estimates

Exhibit 3: Revenue mix by division (MSe FY23)



Source: Morgan Stanley Research estimates

Exhibit 4:
Forecast changes (Old vs. new)

| | New forecast | ts | | | Old forecasts | s | | | Changes | |
|-------------------|--------------|--------|--------|-------------------|---------------|--------|--------|------|---------|------|
| SARm | FY23 | FY24 | FY25 | SARm | FY23 | FY24 | FY25 | FY23 | FY24 | FY25 |
| Revenue | 11,051 | 12,279 | 13,363 | Revenue | 10,964 | 12,190 | 13,250 | 1% | 1% | 1% |
| % ∆ y/y | 25.5% | 11.1% | 8.5% | % ∆ y/y | 24.5% | 11.2% | 8.4% | | | |
| % org. Δ y/y (PF) | 8.7% | 9.5% | 8.5% | % org. ∆ y/y (PF) | 10.0% | 9.5% | 8.4% | | | |
| Stated EBIT | 1,436 | 1,591 | 1,737 | Stated EBIT | 1,350 | 1,506 | 1,622 | 6% | 6% | 7% |
| % of sales | 13.0% | 13.0% | 13.0% | % of sales | 12.3% | 12.4% | 12.2% | | | |
| Adj. EBIT | 1,589 | 1,615 | 1,761 | Adj. EBIT | 1,419 | 1,530 | 1,646 | 12% | 6% | 7% |
| % of sales | 14.4% | 13.2% | 13.2% | % of sales | 12.9% | 12.6% | 12.4% | | | |
| Stated dil EPS | 10.54 | 11.95 | 13.13 | Stated dil EPS | 10.15 | 11.58 | 12.56 | 4% | 3% | 5% |
| Adj. dil EPS | 11.89 | 12.13 | 13.30 | Adj. dil EPS | 10.87 | 11.76 | 12.74 | 9% | 3% | 4% |

 $Source: NB: PF = pro-forma\ method.\ FY23\ MSe\ org.\ growth\ ex-M\&A\ non-PF\ method\ =\ 8.2\%.\ Source:\ Morgan\ Stanley\ Research\ estimates$

Risk Reward – Solutions by STC (7202.SE)

Valuation captures Solutions' KSA ICT services market leadership position

PRICE TARGET SAR 303.00

We value Solutions by STC with a 10-year DCF, using a WACC of 8.5%, and a 2.5% terminal growth rate.



RISK REWARD CHART




Source: Refinitiv, Morgan Stanlev Research

EQUAL-WEIGHT THESIS

- Strongly positioned to help enable KSA
 Vision 2030 by enabling technology adoption in the public and private sectors.
- We forecast Solutions to grow revenues organically at a c. 9% CAGR FY23-26, slightly ahead of its underlying market growth rate. In the context of IT services, this represents a relatively high rate of growth, reflecting KSA's earlier positioning on the IT adoption maturity curve.
- We continue to expect some cost reemergence post COVID-19 pandemic and gross margin volatility (as has historically been the case). We expect adj. EBIT margins to remain broadly around the low-teens % level.
- We see the current valuation as fairly capturing the baseline growth opportunity.

Consensus Rating Distribution



Source: Refinitiv, Morgan Stanley Research

Risk Reward Themes

Secular Growth: Positive

View descriptions of Risk Rewards Themes here

BULL CASE

SAR 406.00

BASE CASE

SAR 303.00

BEAR CASE SA

SAR 180.00

Double-digit organic growth momentum

As was the case over FY19-22, Solutions continues to win large new ICT contracts, driving growth materially above the company's guidance. we forecast c. 29% total growth in FY24 and c. 17% in FY24 (vs. 11% in our base case). Operating leverage drives adj. EBIT margins higher and Solutions sustains >13% margins through the mid-term, and reaches ~14.5% in terminal state. The FY23-26 revenue growth CAGR is c. 14%, c. 6.5% FY27-33. Our bull case equals c. 29x FY24 adj. P/E, or c. 3.4x EV/Sales.

Growth in-line with the market

After MSe c. 17% org. growth in FY22, Solutions continues to deliver strong growth. We forecast c. 9% org. for FY23 (26% total growth), c. 9.5% for FY24. Adj. EBIT margins compress vs. FY22 levels, reflecting M&A impacts and project mix. Adj. EBIT margins ease from MSe 14.4% in FY22 to 13.2% by FY26, as gross margins normalise. The FY27-33 revenue growth CAGR is c. 6%. Adj. EBIT margins improve gradually to ~13.5% in terminal state. Our base case equals c. 25x FY24 adj. P/E, c. 2.7x EV/sales.

Increased competition drives below-market growth

Beyond FY23 (where stated growth is 22%), Solutions' top-line growth moderates below the wider market at, driven by increased competition. Adj. EBIT margins compress to <13% in FY23, and to around 10% in terminal state, as mix shift weighs, currently highermargin work commoditises, and margin improvements in more nascent divisions (e.g. digital) proves relatively limited. The FY23-26 revenue CAGR is c. 6%, c. 3% FY27-33. Our bear case represents c. 17x FY24 adj. P/E, or c. 1.6x EV/Sales.

Risk Reward – Solutions by STC (7202.SE)

KEY EARNINGS INPUTS

| Drivers | 2022 | 2023e | 2024e | 2025e |
|--------------------------------|------|-------|-------|-------|
| Group y/y revenue growth (%) | 22.2 | 25.5 | 11.1 | 8.8 |
| Group adj. EBIT margin (%) | 13.2 | 14.4 | 13.2 | 13.2 |
| Group stated EBITDA margin (%) | 15.8 | 15.5 | 15.5 | 15.5 |

INVESTMENT DRIVERS

- Large new contract wins
- Relative growth of high versus low margin business segments
- Expansion of activities in private sector end market
- M&A inside KSA or in other GCC countries
- Delivery quality on large contracts already being serviced
- 3Q23 results

GLOBAL REVENUE EXPOSURE



Source: Morgan Stanley Research Estimate View explanation of regional hierarchies <u>here</u>

MS ALPHA MODELS

1/5 3 Month MOST Horizon

Source: Refinitiv, FactSet, Morgan Stanley Research; 1 is the highest favored Quintile and 5 is the least favored Ouintile

RISKS TO PT/RATING

RISKS TO UPSIDE

- New contract wins particularly with the KSA government
- International expansion into other GCC countries in the mid-term
- Bolt-on M&A

RISKS TO DOWNSIDE

- Slowdown in contract wins or contract losses once they reach the end of their term
- Weaker than expected delivery on existing large contracts leading to margin compression
- Impairments/provisions on contracts/inventory
- Longer working capital cycles than expected

OWNERSHIP POSITIONING



Refinitiv; MSPB Content. Includes certain hedge fund exposures held with MSPB. Information may be inconsistent with or may not reflect broader market trends. Long/Short Ratio = Long Exposure / Short exposure. Sector % of Total Net Exposure = (For a particular sector: Long Exposure - Short Exposure) / (Across all sectors: Long Exposure - Short Exposure).

MS ESTIMATES VS. CONSENSUS



Source: Refinitiv, Morgan Stanley Research

Financial forecasts

Exhibit 5: Revenue drivers

| Profit & Loss YE 31st Dec - SARm | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023E | FY 2024E | FY 2025E | FY 2026E |
|--|------------|------------|------------|------------|------------|-------------|-------------|-------------|-------------|
| YE 31St Dec - SARM | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | 2025E | 2020E |
| Core ICT Services | 2,566 | 2,960 | 3,744 | 4,231 | 1,324 | 5,742 | 6,058 | 6,376 | 6,707 |
| y/y growth (%) | • | 15.4% | 26.5% | 13.0% | -68.7% | 333.7% | 5.5% | 5.3% | 5.2% |
| y/y cc growth (%) | | 15.4% | 26.5% | 13.0% | 31.2% | 20.7% | 5.5% | 5.3% | 5.2% |
| y/y org. growth (%), (ex FX, ex M&A) | | 15.4% | 26.5% | 13.0% | 31.2% | 5.6% | 5.5% | 5.3% | 5.2% |
| o/w. System Integration | 1,727 | 2,085 | 2,316 | | | | | | |
| y/y growth (%) | | 20.7% | 11.1% | | | | | | |
| o/w. Communication and Internet | 838 | 875 | 1,428 | | | | | | |
| y/y growth (%) | | 4.4% | 63.2% | | | | | | |
| IT Managed and Operational Services | 854 | 1,155 | 1,630 | 1,955 | 529 | 3,317 | 3,881 | 4,249 | 4,621 |
| y/y growth (%) | | 35.3% | 41.1% | 20.0% | -72.9% | 526.8% | 17.0% | 9.5% | 8.7% |
| y/y cc growth (%) | | 35.3% | 41.1% | 20.0% | 13.4% | 42.8% | 17.0% | 9.5% | 8.7% |
| y/y org. growth (%), (ex FX, ex M&A) | | 35.3% | 41.1% | 20.0% | 13.4% | 10.6% | 11.4% | 9.5% | 8.7% |
| o/w. Outsourcing Services | 690 | 903 | 1,229 | | | | | | |
| y/y growth (%) | | 30.8% | 36.1% | | | | | | |
| o/w. Managed Services | 163 | 252 | 401 | | | | | | |
| y/y growth (%) | | 54.4% | 59.1% | | | | | | |
| Digital Services | 622 | 1,142 | 1,518 | 1,629 | 390 | 1,992 | 2,340 | 2,738 | 3,149 |
| y/y growth (%) | | 83.6% | 32.9% | 7.3% | -76.1% | 411.2% | 17.5% | 17.0% | 15.0% |
| y/y cc growth (%) | | 83.6% | 32.9% | 7.3% | -0.4% | 17.3% | 17.5% | 17.0% | 15.0% |
| y/y org. growth (%), (ex FX, ex M&A) | | 83.6% | 32.9% | 7.3% | -0.4% | 15.4% | 17.5% | 17.0% | 15.0% |
| o/w. Cloud Services | 270 | 478 | 677 | | | | | | |
| y/y growth (%) | | 77.0% | 41.7% | | | | | | |
| o/w. Cyber Security | 308 | 430 | 578 | | | | | | |
| y/y growth (%) | | 39.6% | 34.5% | | | | | | |
| o/w. Digital Services | 44 | 234 | 262 | | | | | | |
| y/y growth (%) | | 433.0% | 12.1% | | | | | | |
| Total revenues | 4,041 | 5,257 | 6,891 | 7,816 | 2,243 | 11,051 | 12,279 | 13,363 | 14,477 |
| y/y growth (%) | | 30.1% | 31.1% | 13.4% | 20.1% | 25.5% | 11.1% | 8.8% | 8.3% |
| y/y cc growth (%) | | 30.1% | 31.1% | 13.4% | 20.1% | 25.9% | 11.1% | 8.8% | 8.3% |
| y/y org. growth (%), (ex FX, ex M&A) | | 30.1% | 31.1% | 13.4% | 20.1% | 8.7% | 9.5% | 8.8% | 8.3% |
| y/y org. growth (%), (ex M&A, ex-out not PF) | | 30.1% | 31.1% | 13.4% | 20.1% | 8.2% | 11.1% | 8.8% | 8.3% |

Source: Company data, Morgan Stanley Research estimates (E)

Morgan Stanley | RESEARCH

Exhibit 6: Income statement

| Profit & Loss YE 31st Dec - SARm | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023E | FY 2024E | FY 2025E | FY 2026E |
|--|---------------------|------------|------------|---------------------|---------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Total revenues | 4,041 | 5,257 | 6,891 | 7,816 | 2,243 | 11,051 | 12,279 | 13,363 | 14,477 |
| y/y growth (%) | 4,041 | 30.1% | 31.1% | 13.4% | 20.1% | 25.5% | 11.1% | 8.8% | 8.3% |
| y/y cc growth (%) | | 30.1% | 31.1% | 13.4% | 20.1% | 25.9% | 11.1% | 8.8% | 8.3% |
| y/y org. growth (%), (ex FX, ex M&A) | | 30.1% | 31.1% | 13.4% | 20.1% | 8.7% | 9.5% | 8.8% | 8.3% |
| y/y org. growth (%), (ex M&A, ex-out not PF) | | 30.1% | 31.1% | 13.4% | 20.1% | 8.2% | 11.1% | 8.8% | 8.3% |
| y, y e.g. g.e (70), (ex mar i, ex eacher i) | | 00.170 | 011170 | 10.170 | 20.170 | 0.270 | , | 0.070 | 0.070 |
| Cost of sales | (3,076) | (4,410) | (5,469) | (6,108) | (1,749) | (8,436) | (9,516) | (10,357) | (11,220) |
| Stated gross profit | 965 | 847 | 1,422 | 1,708 | 494 | 2,614 | 2,763 | 3,007 | 3,257 |
| as % of sales | 23.9% | 16.1% | 20.6% | 21.9% | 22.0% | 23.7% | 22.5% | 22.5% | 22.5% |
| Adj. selling and distribution expenses | (113) | (158) | (159) | (196) | (58) | (312) | (350) | (391) | (420) |
| y/y growth | (- / | 39.4% | 1.0% | 23.1% | 38.4% | 26.8% | 12.1% | 11.7% | 7.4% |
| as % of sales | -2.8% | -3.0% | -2.3% | -2.5% | -2.6% | -2.8% | -2.9% | -2.9% | -2.9% |
| Adj. general and administration expenses | (273) | (357) | (429) | (450) | (121) | (715) | (798) | (855) | (927) |
| y/y growth | , | 31.0% | 20.3% | 4.8% | 27.0% | 19.2% | 11.6% | 7.2% | 8.3% |
| as % of sales | -6.7% | -6.8% | -6.2% | -5.8% | -5.4% | -6.5% | -6.5% | -6.4% | -6.4% |
| Net impairments/provisions in COGS | 13 | (32) | (14) | (11) | (26) | (2) | | | |
| Net impairments/provisions below COGS | (7) | 15 | (77) | (163) | (2) | (127) | | | |
| Other income/(losses) | ` <u>6</u> | 74 | `(2) | ` ź | (1) | (34) | | | |
| Amortisation of acquired intangibles | | | | | | (24) | (24) | (24) | (24) |
| Stated EDIT | 570 | 040 | 757 | 000 | 040 | 1 400 | 1 504 | 1 707 | 4.007 |
| Stated EBIT | 572 14.2% | 348 | 757 | 899 11.5% | 313 | 1,436 13.0% | 1,591 13.0% | 1,737 13.0% | 1,887 13.0% |
| as % of sales | | 6.6% | 11.0% | | 14.0% | | | | |
| Adjusted EBIT | 567 | 365 | 848 | 1,073 | 341 15 29/ | 1,589 | 1,615 | 1,761 | 1,911 |
| as % of sales | 14.0% | 6.9% | 12.3% | 13.7% | 15.2% | 14.4% | 13.2% | 13.2% | 13.2% |
| D&A | 43 | 92 | 105 | 208 | 55 | 274 | 310 | 332 | 361 |
| as % of sales | 1.1% | 1.8% | 1.5% | 2.7% | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% |
| o/w. normal depreciation (MSe) | 30 | 54 | 55 | 155 | 42 | 179 | 196 | 200 | 203 |
| as % of sales | 0.7% | 1.0% | 0.8% | 2.0% | 1.9% | 1.6% | 1.6% | 1.5% | 1.4% |
| o/w. lease depreciation | | 17 | 19 | 17 | 4 | 32 | 38 | 41 | 44 |
| o/w. amortisation | 13 | 21 | 31 | 35 | 9 | 39 | 52 | 67 | 90 |
| as % of sales | 0.3% | 0.4% | 0.4% | 0.4% | 0.4% | 0.3% | 0.4% | 0.5% | 0.6% |
| o/w. ppa of intangibles | | | | | | 24 | 24 | 24 | 24 |
| Stated EBITDA | 614 | 440 | 862 | 1,107 | 368 | 1,710 | 1,901 | 2,069 | 2,248 |
| as % of sales | 15.2% | 8.4% | 12.5% | 14.2% | 16.4% | 15.5% | 15.5% | 15.5% | 15.5% |
| Adjusted EBITDA | 610 | 457 | 953 | 1,281 | 396 | 1,839 | 1,901 | 2,069 | 2,248 |
| as % of sales | 15.1% | 8.7% | 13.8% | 16.4% | 17.7% | 16.6% | 15.5% | 15.5% | 15.5% |
| Net finance income/(expense) | 30 | 13 | (1) | 3 | 4 | 52 | 36 | 51 | 66 |
| ` ' ' | | | | | | | | | |
| Stated PBT | 608 | 435 | 754 | 904 | 316 | 1,454 | 1,627 | 1,787 | 1,954 |
| Adj. PBT | 597 | 377 | 847 | 1,076 | 345 | 1,641 | 1,651 | 1,811 | 1,978 |
| Stated tax (Zakat) | (52) | (41) | (52) | (71) | (34) | (185) | (187) | (206) | (225) |
| Tax rate % of stated PBT | -8.5% | -9.4% | -6.9% | -7.9% | -10.6% | -13.7% | -11.5% | -11.5% | -11.5% |
| Adjusted tax (Zakat) | (51) | (36) | (58) | (87) | (37) | (209) | (190) | (208) | (227) |
| Tax rate % of adj. PBT | -8.5% | -9.4% | -6.9% | -8.1% | -10.6% | -13.7% | -11.5% | -11.5% | -11.5% |
| NCIs | | | | | | (5) | (6) | (7) | (8) |
| Stated net income | 556 | 394 | 702 | 833 | 283 | 1,264 | 1,434 | 1,575 | 1,721 |
| Adj. net income | 546 | 342 | 788 | 989 | 309 | 1,426 | 1,455 | 1,575 | 1,742 |
| Adj. for modific | 340 | 372 | 700 | 303 | 303 | 1,720 | 1,755 | 1,000 | 1,172 |
| Average diluted SII | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 |
| Adj. diluted EPS | 4.55 | 2.85 | 6.57 | 8.24 | 2.57 | 11.89 | 12.13 | 13.30 | 14.52 |
| Dividend announced | | | | 475 | | 654 | 696 | 732 | 767 |
| Dividend per share | | | | 4.00 | | 5.50 | 5.85 | 6.15 | 6.45 |
| % stated net income | 0% | 0% | 0% | 57% | 0% | 52% | 49% | 46% | 45% |
| % paid up share capital | 0% | 0% | 0% | 40% | 0% | 55% | 58% | 61% | 64% |
| • • | | | | | | | | | |

Source: Company data, Morgan Stanley Research estimates (E)

Morgan Stanley | RESEARCH

Exhibit 7: Balance sheet

| Balance Sheet YE 31st Dec - SARm | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023E | FY 2024E | FY 2025E | FY 2026E |
|-------------------------------------|------------|------------|------------|------------|------------|-------------|-------------|-------------|-------------|
| 120.00.200 07 | 20.0 | | | | | | | | |
| Accounts receivable | 1,829 | 2,635 | 2,804 | 3,021 | 3,240 | 4,981 | 4,918 | 5,346 | 5,777 |
| As % annualised sales | 45% | 50% | 41% | 39% | 36% | 45% | 40% | 40% | 40% |
| Receivables days | 165 days | 155 days | 144 days | 136 days | 0 days | 154 days | 147 days | 140 days | 140 days |
| Prepayments and other assets | 301 | 157 | 157 | 288 | 151 | 286 | 312 | 340 | 369 |
| As % annualised sales | 7% | 3% | 2% | 4% | 2% | 3% | 3% | 3% | 3% |
| Contract assets | 868 | 1,166 | 1,505 | 1,256 | 1,584 | 1,603 | 2,172 | 2,367 | 2,567 |
| As % annualised sales | 21% | 22% | 22% | 16% | 18% | 15% | 18% | 18% | 18% |
| Other current assets | 140 | 151 | 112 | 274 | 54 | 240 | 250 | 272 | 295 |
| As % annualised sales | 3% | 3% | 2% | 4% | 1% | 2% | 2% | 2% | 2% |
| Total current assets | 3,138 | 4,109 | 4,578 | 4,839 | 5,030 | 7,111 | 7,652 | 8,325 | 9,008 |
| Accounts payable | 1,236 | 1,458 | 1,974 | 1,931 | 1,938 | 3,206 | 3,433 | 3,673 | 3,954 |
| As % annualised sales | -31% | -28% | -29% | -25% | -22% | -29% | -28% | -27% | -27% |
| Deferred revenue | 988 | 1,427 | 1,705 | 2,277 | 2,286 | 3,206 | 3,308 | 3,605 | 3,873 |
| As % annualised sales | -24% | -27% | -25% | -29% | -25% | -29% | -27% | -27% | -27% |
| Contract liabilities | 336 | 452 | 336 | 354 | 364 | 572 | 646 | 715 | 790 |
| As % annualised sales | -8% | -9% | -5% | -5% | -4% | -5% | -5% | -5% | -5% |
| Other current liabilities | 99 | 40 | 53 | 72 | 106 | 145 | 125 | 136 | 148 |
| As % annualised sales | -2% | -1% | -1% | -1% | -1% | -1% | -1% | -1% | -1% |
| Total current liabilities | 2,659 | 3,377 | 4,068 | 4,634 | 4,695 | 7,129 | 7,511 | 8,129 | 8,765 |
| Net working capital | 480 | 732 | 509 | 204 | 335 | (18) | 141 | 196 | 243 |
| As % annualised sales | 12% | 14% | 7% | 3% | 4% | 0% | 1% | 1% | 2% |
| LT equity investments | 0 | | | | | 3 | 3 | 3 | 3 |
| Intangible assets | 64 | 104 | 91 | 98 | 100 | 658 | 658 | 658 | 658 |
| Tangible assets | 102 | 167 | 594 | 551 | 516 | 390 | 325 | 260 | 188 |
| Other non-current assets | 23 | 84 | 79 | 78 | 75 | 66 | 66 | 66 | 66 |
| Total non-current assets | 189 | 354 | 764 | 726 | 691 | 1,117 | 1,052 | 987 | 915 |
| Cash & equivalents | 892 | 414 | 993 | 1,608 | 1,803 | 2,071 | 2,746 | 3,616 | 4,599 |
| ST investments | 230 | | | | | 1,402 | 1,402 | 1,402 | 1,402 |
| ST debt | | | | | | 230 | 230 | 230 | 230 |
| LT debt | | | | | | 507 | 507 | 507 | 507 |
| Net cash/(debt) | 1,123 | 414 | 993 | 1,608 | 1,803 | 2,735 | 3,411 | 4,280 | 5,263 |
| End of service indemnities | 126 | 189 | 295 | 237 | 266 | 409 | 435 | 455 | 465 |
| Lease liabilities | | 54 | 48 | 31 | 29 | 7 | 7 | 7 | 7 |
| Other non-current liabilities | | | | | | , | | | |
| | | | | | | | | | |
| Share capital | 100 | 100 | 1,200 | 1,200 | 1,200 | 1,200 | 1,200 | 1,200 | 1,200 |
| Retained earnings | 1,515 | 1,079 | 610 | 960 | 1,243 | 2,101 | 2,881 | 3,760 | 4,749 |
| Other equity | 50 | 78 | 113 | 111 | 92 | 85 | 43 | (2) | (51) |
| NCI | | | | | | 31 | 37 | 44 | 52 |
| Total equity | 1,665 | 1,257 | 1,924 | 2,271 | 2,535 | 3,418 | 4,161 | 5,001 | 5,949 |
| Total assets | 4,450 | 4,877 | 6,335 | 7,173 | 7,524 | 11,700 | 12,852 | 14,330 | 15,924 |
| Total liabilities and equity | 4,450 | 4,877 | 6,335 | 7,173 | 7,524 | 11,700 | 12,852 | 14,330 | 15,924 |
| | | | | | | | | | |

Source: Company data, Morgan Stanley Research estimates (E)

Morgan Stanley | RESEARCH

Exhibit 8: Cash flow statement

| Cash Flow Statement YE 31st Dec - SARm | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023E | FY 2024E | FY 2025E | FY 2026E |
|---|-----------------------|--------------------|-----------------------|--------------------|--------------------|---------------|--------------------|-------------------|--------------------|
| P&L PBT | 608 | 435 | 754 | 904 | 316 | 1,454 | 1,627 | 1,787 | 1,954 |
| D&A and impairments as a % of sales | 43 1.1% | 92 1.8% | 109 1.6% | 209 <i>2.7%</i> | 55 <i>2.5%</i> | 274 2.5% | 310 <i>2.5%</i> | 332 2.5% | 361 <i>2.5%</i> |
| Employee benefits expense | 53 | 77 | 90 | 60 | 14 | 72 | 78 | 84 | 91 |
| Other impairments/provisions Other non-cash add-backs | 2 | (70) | 91 | 174 | 28 | 130 7 | | | |
| Other non-cash add-backs Other operating cash flows | | (72) | | (0) | | | (0) | (0) | (0) |
| Net finance expense add-back | (30) | (13) | 1 | (3) | (4) | (52) | (36) | (51) | (66) |
| Change in receivables | (870) | (805) | (218) | (368) | (222) | (627) | 63 | (428) | (431) |
| % of sales | -21.5% | -15.3% | -3.2% | -4.7% (1.42) | -9.9% | -5.7% | 0.5% | -3.2% | -3.0% |
| Change in prepayments/other assets % of sales | (164) <i>-4.1%</i> | 122 <i>2.3%</i> | 0.0% | (143) -1.8% | 137 <i>6.1%</i> | (23) -0.2% | (26) -0.2% | (28) -0.2% | (29) -0.2% |
| Change in contract assets | (15) | (290) | (336) | 248 | (328) | (111) | (569) | (195) | (200) |
| % of sales | -0.4% | -5.5% | -4.9% | 3.2% | -14.6% | -1.0% | -4.6% | -1.5% | -1.4% |
| Change in payables | 429 | 191 | 492 | (36) | (16) | 394 | 227 | 240 | 281 |
| % of sales | 10.6% | 3.6% | 7.1% | -0.5% | -0.7% | 3.6% | 1.8% | 1.8% | 1.9% |
| Change in deferred revenue | 507 | 439 | 278 | 572 | 10 | (104) | 102 | 297 | 268 |
| % of sales | 12.6% | <i>8.3%</i> 116 | 4.0% | <i>7.3%</i> 18 | <i>0.4%</i> 10 | -0.9% 84 | 0.8% 74 | <i>2.2%</i> 70 | 1.9% 75 |
| Change in contract liabilities % of sales | (312) <i>-7.7%</i> | 2.2% | (116) <i>-1.7%</i> | 0.2% | 0.5% | 0.8% | 0.6% | 0.5% | 0.5% |
| Other working capital changes | (87) | (26) | 30 | (185) | 213 | 88 | (29) | (11) | (12) |
| % of sales | -2.2% | -0.5% | 0.4% | -2.4% | 9.5% | 0.8% | -0.2% | -0.1% | -0.1% |
| Net change in WC | (512) | (253) | 131 | 107 | (195) | (300) | (159) | (55) | (47) |
| as a % of sales | -12.7% | -4.8% | 1.9% | 1.4% | -8.7% | -2.7% | -1.3% | -0.4% | -0.3% |
| Net interest paid | 31 | 16 | 2 | 3 | 4 | 53 | 36 | 51 | 66 |
| Tax paid | (27) | (100) | (39) | (52) | | (184) | (187) | (206) | (225) |
| End of service payments | (9) | (16) | (20) | (33) | (12) | (43) | (52) | (64) | (80) |
| Cash from operating activities | 160 | 183 | 1,119 | 1,379 | 215 | 1,416 | 1,618 | 1,878 | 2,053 |
| Net capital expenditure | (133) | (179) | (536) | (155) | (19) | (161) | (246) | (267) | (290) |
| as a % of sales | 3.3% | 3.4% | 7.8% | 2.0% | 0.8% | 1.5% | 2.0% | 2.0% | 2.0% |
| Total capex | (133) | (179) | (536) | (155) | (19) | (161) | (246) | (267) | (290) |
| as a % of sales | 3.3% | 3.4% | 7.8% | 2.0% | 0.8% | 1.5% | 2.0% | 2.0% | 2.0% |
| Share issue / (repurchase) | | | | | | | | | |
| Cash dividends paid | (300) | (800) | | (400) | | (595) | (654) | (696) | (732) |
| Net disposals / (acquisitions) | | 100 | | | | (415) | | | |
| Lease repayments Other financing cash flows | | (13) | (4) | (29) (181) | (1) | (39) | (42) | (45) | (49) |
| Other investing cash flows | 570 | 230 | | (101) | | 1,298 | | | |
| Issue of debt | | | | | | 40 | | | |
| Repayment of debt | | | | | | | | | |
| Cash FX impact | | | | | | (18) | | | |
| FCFE | 27 | (9) | 579 | 1,195 | 196 | 1,211 | 1,324 | 1,559 | 1,707 |
| as % of adj. EBIT | 4.8% | -2.3% | 68.3% | 111.4% | 57.4% | 76.2% | 82.0% | 88.5% | 89.3% |
| y/y growth (%) | 0.70/ | -131.5% | -6909.5% | 106.4% | -35.9% | -37.9% | 9.3% | 17.7% | 9.5% |
| as % of sales | 0.7% | -0.2% | 8.4% | 15.3% | 8.7% | 11.0% | 10.8% | 11.7% | 11.8% |
| FCFF | 4 | (12) | 594 | 1,224 | 204 | 1,205 | 1,344 | 1,578 | 1,727 |
| as % of adj. EBIT | 0.8% | -3.4% | 70.1% | 114.0% | 59.8% | 75.8% | 83.2% | 89.6% | 90.4% |
| y/y growth (%) | 2 12/ | -383.8% | -4939.1% | 105.8% | -35.5% | -39.3% | 11.5% | 17.4% | 9.5% |
| as % of sales | 0.1% | -0.2% | 8.6% | 15.7% | 9.1% | 10.9% | 10.9% | 11.8% | 11.9% |

Source: Company data, Morgan Stanley Research estimates (E)

Risk Reward Reference links

- 1. View explanation of Options Probabilities methodology Options_Probabilities_Exhibit_Link.pdf
- 2. View descriptions of Risk Rewards Themes RR_Themes_Exhibit_Link.pdf
- 3. View explanation of regional hierarchies Microsoft PowerPoint Exhibit Links.pptx
- 4. View explanation of 'Indicator of Change' methodology -

 ${\sf ESG_Indicator_of_Change_External_Link.pdf}$

5. View explanation of Theme/Exposure methodology -

 ${\sf ESG_Sustainable_Solutions_External_Link.pdf}$

6. View explanation of HERS methodology - ESG_HERS_External_Link.pdf



Disclosure Section

The information and opinions in Morgan Stanley Research were prepared or are disseminated by Morgan Stanley Europe S.E., regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin) and/or Morgan Stanley & Co. International plc, authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. Morgan Stanley & Co. International plc disseminates in the UK research that it has prepared, and which has been prepared by any of its affiliates, only to persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"); (ii) are persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order; or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended) may otherwise lawfully be communicated or caused to be communicated. As used in this disclosure section, Morgan Stanley includes RMB Morgan Stanley Proprietary Limited, Morgan Stanley Europe S.E., Morgan Stanley & Co International plc and its affiliates.

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Henrik Herbst; George W Webb; Adam Wood.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictpolicies. A Portuguese version of the policy can be found at www.morganstanley.com.br

Important Regulatory Disclosures on Subject Companies

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts' or strategists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Morgan Stanley trades or may trade as principal in the debt securities (or in related derivatives) that are the subject of the debt research report.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

Global Stock Ratings Distribution

(as of July 31, 2023)

The Stock Ratings described below apply to Morgan Stanley's Fundamental Equity Research and do not apply to Debt Research produced by the Firm.

For disclosure purposes only (in accordance with FINRA requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

| | Coverag | e Universe | Inves | stment Banking Clients | s (IBC) | Other Material Investment Services Clients (MISC) | | |
|--------------------------|---------|------------|-------|------------------------|-------------------------|--|--------------------------|--|
| Stock Rating Category | Count | % of Total | Count | % of Total IBC | % of Rating Category | Count | % of Total Other MISC | |
| Overweight/Buy | 1347 | 37% | 276 | 43% | 20% | 609 | 39% | |
| Equal-weight/Hold | 1659 | 46% | 294 | 46% | 18% | 717 | 46% | |
| Not-Rated/Hold | 3 | 0% | 0 | 0% | 0% | 1 | 0% | |
| Underweight/Sell | 604 | 17% | 69 | 11% | 11% | 227 | 15% | |
| Total | 3.613 | | 639 | | | 1554 | | |

Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Due to rounding off of decimals, the percentages provided in the "% of total" column may not add up to exactly 100 percent.

Analyst Stock Ratings

Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

Analyst Industry Views

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below. Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below. Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Stock Price, Price Target and Rating History (See Rating Definitions)



Price Target History: 11/1/21: 205; 5/12/22: 250; 8/10/22: 262.5; 11/2/22: 270; 12/12/22: 277.5; 2/28/23: 268; 5/16/23: 287; 7/5/23: 295

Source: Morgan Stanley Research Date Format: MM/DD/YY Price Target -- No Price Target Assigned (NA) Stock Price (Not Covered by Current Analyst) -- Stock Price (Covered by Current Analyst) -- Stock and Industry Ratings (abbreviations below) appear as + Stock Rating/Industry View Stock Ratings: Overweight (O) Equal-weight (E) Underweight (U) Not-Rated (NR) No Rating Available (NA) Industry View: Attractive (A) In-line (I) Cautious (C) No Rating (NR)

Effective January 13, 2014, the stocks covered by Morgan Stanley Asia Pacific will be rated relative to the analyst's industry (or industry team's) coverage.

Effective January 13, 2014, the industry view benchmarks for Morgan Stanley Asia Pacific are as follows: relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Important Disclosures for Morgan Stanley Smith Barney LLC & E*TRADE Securities LLC Customers

Important disclosures regarding the relationship between the companies that are the subject of Morgan Stanley Research and Morgan Stanley Smith Barney LLC or Morgan Stanley or any of their affiliates, are available on the Morgan Stanley Wealth Management disclosure website at www.morganstanley.com/online/researchdisclosures. For Morgan Stanley specific disclosures, you may refer to www.morganstanley.com/researchdisclosures.

Each Morgan Stanley research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC and E*TRADE Securities LLC. This review and approval is conducted by the same person who reviews the research report on behalf of Morgan Stanley. This could create a conflict of interest.

Other Important Disclosures

Morgan Stanley Research policy is to update research reports as and when the Research Analyst and Research Management deem appropriate, based on developments with the issuer, the sector, or the market that may have a material impact on the research views or opinions stated therein. In addition, certain Research publications are intended to be updated on a regular periodic basis (weekly/monthly/quarterly/annual) and will ordinarily be updated with that frequency, unless the Research Analyst and Research Management determine that a different publication



schedule is appropriate based on current conditions.

Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.

Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.

Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (http://www.morganstanley.com/terms.html). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use (http://www.morganstanley.com/terms.html). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html).

If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research. Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell on the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

The "Important Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.

To our readers based in Taiwan or trading in Taiwan securities/instruments: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Any non-customer reader within the scope of Article 7-1 of the Taiwan Stock Exchange Recommendation Regulations accessing and/or receiving Morgan Stanley Research is not permitted to provide Morgan Stanley Research to any third party (including but not limited to related parties, affiliated companies and any other third parties) or engage in any activities regarding Morgan Stanley Research which may create or give the appearance of creating a conflict of interest. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A. located at Av. Brigadeiro Faria Lima, 3600, 6th floor, São Paulo - SP, Brazil; and is regulated by the Comissão de Valores Mobiliários; in Mexico by Morgan Stanley México, Casa de Bolsa, S.A. de C.V which is regulated by Comision Nacional Bancaria y de Valores. Paseo de los Tamarindos 90, Torre 1, Col. Bosques de las Lomas Floor 29, 05120 Mexico City; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Morgan Stanley Bank Asia Limited; in Singapore by Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research) and by Morgan Stanley Bank Asia Limited, Singapore Branch (Registration number T14FC0118)); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited having



Corporate Identification No (CIN) U22990MH1998PTC115305, regulated by the Securities and Exchange Board of India ("SEBI") and holder of licenses as a Research Analyst (SEBI Registration No. INH000001105); Stock Broker (SEBI Stock Broker Registration No. INZ000244438), Merchant Banker (SEBI Registration No. INM000011203), and depository participant with National Securities Depository Limited (SEBI Registration No. IN-DP-NSDL-567-2021) having registered office at 18th Floor, Tower 2, One World Center, Plot-841, Jupiter Textile Mill Compound, Senapati Bapat Marg, Lower Parel, Mumbai 400013, India Telephone no. +91-22-61181000; Compliance Officer Details: Mr. Anil Shenoy, Tel. No.: +91-22-61181000 or Email: Anil. Shenoy@morganstanley.com; Grievance officer details: Mr. Anil Shenoy, Tel. No.: +91-22-61181000 or Email: msic-compliance@morganstanley.com; in Canada by Morgan Stanley Canada Limited; in Germany and the European Economic Area where required by Morgan Stanley Europe S.E., authorised and regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin) under the reference number 149169; in the US by Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority, disseminates in the UK research that it has prepared, and research which has been prepared by any of its affiliates, only to persons who (i) are investment professionals falling within Article 49(2)(a) to (d) of the Order; or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended) may otherwise lawfully be communicated or caused to be communicated. RMB Morgan Stanley Proprietary Limited is a member of the JSE Limited and A2X (Pty) Ltd. RMB Morgan Stanley Proprietary Limited is a joint venture owned equally by Morgan Stanley International

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at Professional Clients only, as defined by the DFSA. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria to be a Professional Client. A distribution of the different MS Research ratings or recommendations, in percentage terms for Investments in each sector covered, is available upon request from your sales representative.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Indicators and trackers referenced in Morgan Stanley Research may not be used as, or treated as, a benchmark under Regulation EU 2016/1011, or any other similar framework.

The issuers and/or fixed income products recommended or discussed in certain fixed income research reports may not be continuously followed. Accordingly, investors should regard those fixed income research reports as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or individual fixed income products. Morgan Stanley may hold, from time to time, material financial and commercial interests regarding the company subject to the Research report.

Registration granted by SEBI and certification from the National Institute of Securities Markets (NISM) in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

INDUSTRY COVERAGE: EEMEA - Technology

| COMPANY (TICKER) | RATING (AS OF) | PRICE* (08/09/2023) |
|----------------------------|----------------|---------------------|
| George W Webb | | |
| Solutions by STC (7202.SE) | E (05/12/2022) | SAR 320.80 |

Stock Ratings are subject to change. Please see latest research for each company.

© 2023 Morgan Stanley

^{*} Historical prices are not split adjusted.